ANNA NEUZIL
LARGO, FL
Browse related groups: FL Actelion Pharmaceuticals US, Inc. All categories
General Payments — all program years on this page
$1,805.79
- Category: General Payments
- Program years: PY2022–2024
- Record count: 19
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $649.42 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $649.42 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $241.37 | 2 |
| Otsuka America Pharmaceutical, Inc. | $124.95 | 1 |
| Novo Nordisk AS | $102.21 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $101.18 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $79.71 | 2 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078878958 | Actelion Pharmaceuticals US, Inc. | $123.69 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1078878968 | Actelion Pharmaceuticals US, Inc. | $117.68 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1108582021 | Novo Nordisk Inc | $102.21 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1118267727 | Boehringer Ingelheim Pharmaceuticals, Inc. | $101.18 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1119148465 | Otsuka America Pharmaceutical, Inc. | $124.95 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1145420812 | Takeda Pharmaceuticals U.S.A., Inc. | $33.90 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1145420816 | Takeda Pharmaceuticals U.S.A., Inc. | $45.81 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.